Company
OBaris AG
Incorporated
March 2024
Headquarter
Schlieren
Support
Providing a painless alternative to injectable drugs.
Our unique platform aims at shifting the current paradigm from injectables to a simple, non-invasive formulation that enables safe and efficacious delivery of a variety of macromolecular drugs across multiple therapeutic indications. We aim to access the rapidly growing market of therapeutic peptides, with ca. 80 registered drugs and an overall size of ca. CHF 40 billion in 2023 with CAGR of ca. 10%. The business model of the prospective startup company will be based on a dual mode, including strategic partnerships with leading pharmaceutical companies and simultaneous development of our own product.
